|
|
Silk Road Medical Inc (SILK) |
|
Price: $27.4900
$-0.01 
-0.036%
|
| Day's High:
| $27.51
| Week Perf:
| 1.1 %
|
| Day's Low: |
$ 27.49 |
30 Day Perf: |
1.4 % |
| Volume (M): |
2,309 |
52 Wk High: |
$ 27.51 |
| Volume (M$): |
$ 63,472 |
52 Wk Avg: |
$18.21 |
| Open: |
$27.49 |
52 Wk Low: |
$6.08 |
|
|
| Market Capitalization (Millions $) |
1,089 |
| Shares
Outstanding (Millions) |
40 |
| Employees |
474 |
| Revenues (TTM) (Millions $) |
190 |
| Net Income (TTM) (Millions $) |
-57 |
| Cash Flow (TTM) (Millions $) |
-6 |
| Capital Exp. (TTM) (Millions $) |
2 |
Silk Road Medical Inc
Silk Road Medical Inc is a medical technology company that specializes in developing and commercializing novel devices and treatment options for patients suffering from vascular diseases. It was founded in Silicon Valley in 2007, and has rapidly risen to become a trusted brand in the healthcare industry.
The company's flagship product is the ENROUTEe Transcarotid Stent System, which is used to treat carotid artery disease, a potentially deadly condition that can lead to stroke. The ENROUTEe technology offers a minimally invasive solution for patients that enables the treatment of carotid artery disease without the need for open surgery.
The Silk Road Medical team comprises world-renowned experts in vascular surgery, interventional cardiology, and biomedical engineering. The company's research is backed by a comprehensive intellectual property portfolio that includes patents, trade secrets, and trademarks.
Silk Road Medical has established a global network of distribution partners to ensure that its medical devices reach the widest possible audience. The company has commercial offices in Europe and Asia, as well as in the United States. Additionally, Silk Road Medical has a robust digital platform that allows physicians and patients to access medical information, clinical studies, and educational resources.
The company has received numerous accolades for its innovation, including the Scientific Achievement Award from the Society for Vascular Surgery. Silk Road Medical has also been recognized by major publications such as Forbes and Inc. Magazine for its growth and impact on the healthcare industry.
In summary, Silk Road Medical Inc is a highly respected medical technology company that is dedicated to improving the lives of patients with vascular diseases through innovative solutions, advanced research, and education.
Company Address: 1213 Innsbruck Dr. Sunnyvale 94089 CA
Company Phone Number: 720-9002 Stock Exchange / Ticker: NASDAQ SILK
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Management Announcement
Published Tue, Jul 30 2024 12:00 PM UTC
Silk Road Medical: Revolutionizing Transcarotid Artery Revascularization with Groundbreaking Milestone of 100,000 Procedures
Study-backed and supported by extensive clinical publications, Silk Road Medical Inc has once again proven its expertise in delivering positive outcomes through its innovative Transcarotid Artery Revascularization (TCAR) procedures. This milestone...
|
| Silk Road Medical Inc
Silk Road Medical Inc, a company committed to reducing the risk of stroke and its devastating consequences, recently announced its participation in the BofA Securities 2024 Healthcare Conference. This news comes as the company unveils its latest innovation, the ENROUTE Transcarotid Neuroprotection System PLUS (NPS PLUS), which enhances its TCAR portfolio.
The fiscal span closing on March 31, 2024, had both positive and negative aspects for Silk Road Medical Inc. On one hand, the company reduced its losses per share from $-0.43 to $-0.36 compared to the previous year. However, it experienced a shortfall increase from $-0.31 per share in the prior reporting period. It is important to note that the revenue grew significantly by 18.365% to $47.50 million, a notable improvement from $40.13 million in the same reporting period a year prior. Sequentially, the revenue grew by 0.476% from $47.28 million. Comparing Silk Road Medical Inc's revenue growth to other companies in the Medical Equipment & Supplies sector, it is evident that the company performed exceptionally well. In the first quarter of 2024, most companies in this sector had an average revenue elevation of 6.11% from the first quarter of 2023.
|
| Product Service News
Published Tue, Apr 2 2024 8:30 PM UTC
Silk Road Medical Enhances TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUSSUNNYVALE, Calif., April 02, 2024 - Silk Road Medical, Inc. (Nasdaq: SILK), a leading company dedicated to reducing the risk of stroke and its detrimental consequences, has recently unveiled its latest innovation, the ENROUTE Transcarotid Neuroprotection System PLUS (NPS ...
|
| Silk Road Medical Inc
Silk Road Medical Inc, a company focused on reducing the risk of stroke, recently released its financial results for the fiscal interval ending December 31, 2023. The company reported a decrease in loss per share, an improvement in EPS, and significant revenue growth. However, there are some concerning factors such as a net shortfall and an increase in inventories and accounts receivable.
In terms of earnings per share (EPS), Silk Road Medical Inc has made progress compared to the previous year. Their loss per share decreased to $-0.31 from $-0.33, and EPS improved from $-0.33 per share in the prior reporting period. This indicates that the company is making efforts to reduce losses and increase profitability.
|
| Silk Road Medical Inc
Silk Road Medical Inc Defies the Odds with Impressive Revenue Growth
In recent years, Silk Road Medical Inc has been an exciting player in the stock market, and the latest financial reporting period shows why. Despite challenging economic conditions, the company has managed to achieve remarkable results, positioning itself as a standout performer in the Medical Equipment & Supplies industry.
For the fiscal period closing September 30, 2023, Silk Road Medical Inc reported a 18.759% increase in revenue, soaring to $44.39 million compared to $37.37 million in the same period a year prior. This significant growth is a testament to the company's unwavering commitment to success and its ability to navigate obstacles with ease.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.42 $ |
| Revenues (TTM) |
4.79 $
|
| Cash Flow (TTM) |
- |
| Cash |
4.34 $
|
| Book Value |
3.9 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.42 $
|
| Revenues (TTM) |
4.79 $ |
| Cash Flow (TTM) |
- |
| Cash |
4.34 $
|
| Book Value |
3.9 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
On February 28 2024 the Silk Road Medical Inc provided following guidance
In the fourth quarter of 2023, Silk Road Medical reported a significant increase in revenue, with total revenue reaching a record high for the company. The company's focus on reducing the risk of stroke has clearly resonated with customers, leading to a strong performance in sales.
For the full year of 2023, Silk Road Medical also saw positive results, with steady growth in revenue and an increase in market share. The company's commitment to providing innovative medical solutions for stroke prevention has positioned them as a leader in the industry.
Looking ahead to 2024, Silk Road Medical is optimistic about future growth and profitability. The company has provided financial estimates for ...
|
|
|
